OTCEquity is a premier site for updated news and financial information regarding penny stocks and small cap companies. We offer a free newsletter, articles about penny stock trading, otc bulletin board analytical data and original news stories about the penny stock companies you are interested in.
Biotech companies continue to offer investors a unique opportunity for potentially massive gains yet there are always a number of risks involved with speculative plays. That being said we have identified four biotech companies that you may want to put … Continue reading →
The road to FDA approval for Cell Therapeutics, Inc. (NASDAQ: CTIC) has been one littered with speed bumps and potholes yet the biotechnology company now sits just a few months away from potentially clearing the final hurdle and advancing their … Continue reading →
Posted in Articles, NASDAQ, Penny Stocks
|
Tagged cell therapeutics, CTIC, fda, fda approval, investors, NASDAQ, non-hodgkin's lymphoma, penny stocks, pixantrone
|
It has been more than a year since shares in Cell Therapeutics Inc. (NASDAQ: CTIC) tanked following a unanimous 9-0 vote by the FDA rejecting the biotechnology company’s drug pixantrone for the treatment of non-Hodgkin’s lymphoma. Since that time CTIC … Continue reading →
Posted in Articles, NASDAQ, Small Cap
|
Tagged cell therapeutics, CTIC, fda, investors, james bianco, lymphoma, NASDAQ, penny stocks, pix301, pixantrone, tumors
|
Questions surrounding Cell Therapeutics Inc. (NASDAQ: CTIC) abound as investors continue to place their bets on whether the biopharmaceutical company has the ability to eliminate questions of effectiveness and safety concerning their lymphoma drug pixantrone and bring the drug to market. Continue reading →
